Mass General Brigham IRB
APPROVAL EFFECTIVE DATE
4/21/2021

Are you interested in participating in research?

The McLean Hospital Geriatric Psychiatry Research Program is interested in learning about the effects of dronabinol, a synthetic form of THC, on agitation and aggression in Alzheimer's Disease.

You may be eligible to participate in a research study at McLean Hospital, an affiliate of Harvard Medical School if you:

- Are between the ages of 60-95 years old, inclusive
- Have a diagnosis of probable Alzheimer's Dementia and experience agitation or aggression
- Are fluent in English

This study consists of:

- Five in-person visits to McLean Hospital over the course of three weeks. You will have the option to complete portions of these visits remotely.
- In person visits will include a blood draw, vital signs, an EKG, and tests of your memory and thinking.
- Taking a capsule containing either dronabinol or a placebo (sugar pill) twice per day.
- You will receive up to $100 in compensation for participating in this study.
- To enroll in this study or for further information about this study please contact **Mia Drury at mdrury@mclean.harvard.edu**.

Mia Drury; GPRP mdrury@mclean.harvard.edu
Mia Drury; GPRP mdrury@mclean.harvard.edu
Mia Drury; GPRP mdrury@mclean.harvard.edu
Mia Drury; GPRP mdrury@mclean.harvard.edu